Clairity Raises $43 Million in Series B to Launch First FDA-Authorized AI Platform for Breast Cancer Risk Prediction

Clairity在B轮融资中筹集了4300万美元，用于推出首个获FDA授权的乳腺癌风险预测人工智能平台。

With backing from leading healthcare investors, Clairity accelerates its mission to predict and prevent breast cancer and expand into cardiovascular disease

在领先医疗保健投资者的支持下，Clairity 加速了其预测和预防乳腺癌的使命，并扩展到心血管疾病领域。

BOSTON, November 13, 2025-- Clairity, Inc., an AI-driven precision health company pioneering image-based risk prediction, today announced the closing of a $43 million Series B financing. The funds will be used to commercialize the company’s product, Clairity Breast, the first FDA-authorized artificial intelligence platform that predicts a woman’s five-year risk of breast cancer directly from a routine mammogram, and to advance development of Clairity Breast 3D and Clairity Heart, Clairity’s next offering focused on predicting cardiovascular risk from the same routine imaging exam..

波士顿，2025年11月13日——Clairity, Inc.是一家以人工智能驱动的精准健康公司，专注于基于图像的风险预测。该公司今日宣布完成了4300万美元的B轮融资。这笔资金将用于将其产品Clairity Breast商业化，这是首个获得FDA授权的人工智能平台，可直接通过常规乳腺X光检查预测女性五年内患乳腺癌的风险。此外，资金还将用于推进Clairity Breast 3D和Clairity Heart的开发，Clairity的下一款产品将专注于通过同样的常规影像检查预测心血管疾病风险。

The round was led by ACE Global Equity and Santé Ventures, with continued participation from the Breast Cancer Research Foundation (BCRF) and several new investors. The strong commitment from the syndicate reflects broad confidence in Clairity’s mission to transform how breast cancer is found, managed, and ultimately prevented, and in the power of the company’s AI platform to extend into other areas of population health..

本轮融资由ACE全球股权和桑特风险投资领投，乳腺癌研究基金会（BCRF）持续参与，同时还有数名新投资者加入。财团的坚定承诺反映了对Clairity使命的广泛信心，即变革乳腺癌的发现、管理和最终预防方式，并相信公司的人工智能平台能够扩展到人口健康的其他领域。

The new funding will allow Clairity to accelerate U.S. commercialization, expand partnerships with leading imaging centers and health systems, and drive continued development of Clairity’s broader predictive health platform.

新资金将使Clairity能够加速美国商业化进程，扩大与领先的影像中心和卫生系统的合作伙伴关系，并推动Clairity更广泛的预测健康平台的持续开发。

Following the successful FDA authorization of Clairity Breast and its initial rollout to marquee health systems, the company is expanding its pipeline to include new AI-based predictive offerings for other major diseases, leveraging the same deep learning framework on which Clairity Breast was built.

在Clairity Breast成功获得FDA批准并初步推广到知名卫生系统后，该公司正在扩展其产品线，以包括针对其他主要疾病的新AI预测产品，这些产品将利用构建Clairity Breast的相同深度学习框架。

The Series B financing will also support reimbursement initiatives and partnerships aimed at making Clairity Breast accessible across community imaging centers nationwide..

B轮融资还将支持报销计划和合作伙伴关系，旨在使Clairity Breast在全国范围内的社区影像中心均可使用。

“For decades, we have relied on mammography to detect cancer only after it is visible,” said Connie Lehman, MD, PhD, Founder of Clairity. “With Clairity Breast, we can now use the same images to predict who may be at risk over the next five years, supporting earlier intervention, fewer late-stage diagnoses, and more lives saved.

“几十年来，我们一直依赖乳腺X光摄影术来检测已经可见的癌症，” Clairity创始人康妮·莱曼医学博士说道，“通过Clairity Breast，我们现在可以使用相同的图像预测未来五年内谁可能有风险，从而支持更早的干预、减少晚期诊断并挽救更多生命。”

This is the future of breast cancer care: predictive, personalized, and preventive.”.

这就是乳腺癌护理的未来：预测性、个性化和预防性。

“Our fundraising is about more than capital; it’s about momentum,” said Jeff Luber, Clairity’s President and CEO. “With FDA authorization in hand and commercial partnerships underway, Clairity Breast is poised to redefine how the world approaches breast cancer. We’re proud to stand at the forefront of a paradigm shift—from detection to prevention—and to deliver technology that empowers women and their doctors to predict risk to support action before cancer starts.”.

“我们的募资不仅仅是关于资金，更是关于发展势头，”Clairity的总裁兼首席执行官杰夫·卢伯表示。“在获得FDA授权并启动商业合作之际，Clairity Breast准备重新定义世界应对乳腺癌的方式。我们很自豪站在这一范式转变的前沿——从检测到预防——并提供技术来帮助女性及其医生预测风险，从而在癌症发生之前采取行动。”

“Clairity represents a rare combination of scientific rigor, regulatory validation, and transformative clinical impact,” said Gabriella Antici, Partner and Chief Investment Officer, ACE Global Equity. “Predictive imaging is the next frontier in oncology, and Clairity Breast is the first real-world embodiment of that promise.”.

“Clairity 代表着科学严谨性、监管验证和变革性临床影响的罕见结合，”ACE 全球股权合伙人兼首席投资官加布里埃拉·安蒂奇表示。“预测性成像是肿瘤学的下一个前沿领域，而 Clairity Breast 是这一承诺在现实世界中的首次体现。”

“BCRF has long believed that prevention is the ultimate cure,” said Donna McKay, President and CEO, Breast Cancer Research Foundation. “Clairity’s technology embodies that vision, turning existing imaging infrastructure into a proactive tool for risk stratification toward earlier interventions that can save lives.

“BCRF始终相信预防是最终的治愈之道，”乳腺癌研究基金会总裁兼首席执行官唐娜·麦凯表示。“Clairity的技术体现了这一愿景，将现有的成像基础设施转变为一种用于风险分层的前瞻性工具，从而实现更早期的干预，挽救生命。”

We’re proud to continue supporting their work as they bring this innovation to women everywhere.”.

我们很自豪能继续支持他们的工作，因为他们将这项创新带给世界各地的女性。”

“Santé is proud to support Clairity in advancing a new era of predictive breast health,” said Kevin Lalande, Founding Managing Director and Chief Investment Officer of Santé Ventures. “By pairing clinically validated AI with scalable access channels, Clairity exemplifies the type of innovation that can help drive better outcomes for patients and greater cost efficiency across the healthcare system.”.

“Santé 很荣幸能够支持 Clairity 开创乳腺健康预测的新时代，” Santé Ventures 创始董事总经理兼首席投资官 Kevin Lalande 表示。“通过将经过临床验证的人工智能与可扩展的访问渠道相结合，Clairity 展现了能够帮助改善患者治疗效果并提高整个医疗系统成本效率的创新类型。”

“Clairity’s work represents exactly the kind of innovation we need in healthcare, where data and AI move us from reacting to disease to preventing it,” said Joe Kiani, Founder and Executive Chairman of Willow Laboratories, and Founder of global medical technology company, Masimo (NASDAQ: MASI). “By transforming routine imaging into a window of prediction, Clairity empowers physicians and patients alike to act earlier, which should lead to better outcomes.” Mr.

“Clairity 的工作代表了我们在医疗保健领域所需要的创新，数据和人工智能使我们从对疾病的反应转向预防疾病，”Willow Laboratories 创始人兼执行主席、全球医疗技术公司 Masimo（纳斯达克股票代码：MASI）创始人 Joe Kiani 表示。“通过将常规成像转化为预测的窗口，Clairity 赋予医生和患者更早采取行动的能力，这应该会带来更好的结果。”

Kiani joins Clairity as investor and board member..

基亚尼以投资者和董事会成员的身份加入克莱尔蒂。

TCB Capital Advisors (“TCB”) served as exclusive financial advisor to Clairity with respect to the Series B financing.

TCB Capital Advisors（“TCB”）担任了Clairity关于B轮融资的独家财务顾问。

About Clairity, Inc.

关于Clairity公司

Clairity is an AI-powered precision health company transforming medical imaging into a predictive tool for early risk assessment. Its flagship product, Clairity Breast, is the first FDA-cleared platform to estimate a woman’s five-year breast cancer risk directly from a routine mammogram. By shifting care from detection to prevention, Clairity empowers health systems, radiologists, and women to act earlier, save lives, and lower the overall cost of cancer care..

Clairity是一家利用人工智能的精准健康公司，将医学影像转化为早期风险评估的预测工具。其旗舰产品Clairity Breast是首个获得FDA批准的平台，能够直接通过常规乳腺X光片估算女性五年内患乳腺癌的风险。通过将医疗重点从检测转向预防，Clairity助力健康系统、放射科医生和女性更早采取行动，挽救生命，并降低癌症护理的总体成本。

For more information, visit www.clairity.com.

欲了解更多信息，请访问 www.clairity.com。

Contact:

联系人：

Investor Contact: Jenna Barton; jbarton@clairity.com

投资者联系人：詹娜·巴顿；jbarton@clairity.com